Validating new symptom emergence as a patient-centric outcome measure for PD clinical trials
Further validation using data sets with frequent administration of MDS-UPDRS is necessary to assess value of this approach as an outcome measure in PD clinical trials.
Authors
- Haotian Zou (ORCID: https://orcid.org/0000-0002-3595-8716)
- Jesse M. Cedarbaum (ORCID: https://orcid.org/0000-0002-5146-8784)
- Glenn T. Stebbins (ORCID: https://orcid.org/0000-0001-7905-9336)
- Tanya Simuni (ORCID: https://orcid.org/0000-0002-2347-1644)
- Sheng Luo (ORCID: https://orcid.org/0000-0003-4214-5809)
Institutions
- Northwestern University (US)
- Rush University Medical Center (US)
- Duke University (US)
- Yale University (US)
Publication Details
- Journal
- Parkinsonism & Related Disorders
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1016/j.parkreldis.2024.107118
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Michael J. Fox Foundation for Parkinson's Research
- Parkinson's Disease Foundation
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Davis Phinney Foundation
- Neurocrine Biosciences
- Denali Therapeutics
- Amneal Pharmaceuticals
- University of Oxford
- Newcastle University
- University of Glasgow
- IXICO
- National Institute of Neurological Disorders and Stroke